

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10579229	
	Filing Date		2007-04-06	
	First Named Inventor	Vasso Apostolopoulos		
	Art Unit	1632		
	Examiner Name			
Attorney Docket Number		3489-103		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0175617	EP	B1	1991-10-30	Cytogen Corporation		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10579229
Filing Date	2007-04-06
First Named Inventor	Vasso Apostolopoulos
Art Unit	1632
Examiner Name	
Attorney Docket Number	3489-103

1	Tang, Choon K., et al., "Mannan-mediated gene delivery for cancer immunotherapy," Immunology, 120(3): 325-335 (March 2007)	<input type="checkbox"/>
2	Apostolopoulos, Vasso, et al., "Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway," Eur. J. Immunol. 30(6): 1714-1723 (June 2000)	<input type="checkbox"/>
3	Sasaki, Shin, et al., "Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine," Eur. J. Immunol. 27(12): 3121-3129 (December 1997)	<input type="checkbox"/>
4	Apostolopoulos, Vasso, et al., "Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses," Proc. Natl. Acad. Sci. USA, 92: 10128-10132 (October 1, 1995)	<input type="checkbox"/>
5	Supplementary European Search Report for European Application 04797013 dated January 8, 2008	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.